Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Biomimetic astrocyte cell membrane-fused nanovesicles for protecting neurovascular units in hypoxic ischemic encephalopathy.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE
- Publication Information:
Original Publication: London : BioMed Central, 2003-
- Subject Terms:
- Abstract:
Hypoxic ischemic encephalopathy (HIE) refers to neonatal hypoxic brain injury caused by severe asphyxia during the perinatal period. With a high incidence rate and poor prognosis, HIE accounts for 2.4% of the global disease burden, imposing a heavy burden on families and society. Current clinical treatment for HIE primarily focuses on symptomatic management and supportive care. Therefore, the developments of effective treatment strategies and new drug formulations are critical for improving the prognosis of HIE patients. In order to protect the compromised neurovascular units after HIE, we prepared membrane-fused nanovesicles for delivering rapamycin and si EDN1 (TRCAM@RAPA@si EDN1). Due to the homotypic targeting feature of membrane-fused nanovesicles, we employed astrocyte membranes as synthetic materials to improve the targeting of astrocytes in brain while reducing the clearance of nanovesicles by circulatory system. Additionally, the surface of cell membrane was modified with CXCR3 receptors, enhancing the homing of nanovesicles to infarcted lesions. Lipid vesicles were modified with TK and RVG29 transmembrane peptides, enabling responsive release of internal drugs and blood-brain barrier penetration. Internally loaded rapamycin could promote protective autophagy in astrocytes, improve cellular oxidative stress, while si EDN1 could reduce the expression level of endothelin gene, thereby reducing secondary damage to neurovascular units.
Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
- References:
Obstet Gynecol. 2024 Jan 1;143(1):67-81. (PMID: 37797337)
Prog Neurobiol. 2021 Apr;199:101963. (PMID: 33249091)
Circ Res. 2017 Jan 6;120(1):85-98. (PMID: 27756792)
Pharmacol Ther. 2021 Sep;225:107848. (PMID: 33823204)
Int J Mol Sci. 2021 Apr 20;22(8):. (PMID: 33924191)
Transl Stroke Res. 2019 Feb;10(1):104-111. (PMID: 29476447)
Angew Chem Int Ed Engl. 2020 Aug 24;59(35):15176-15180. (PMID: 32431060)
Int J Mol Sci. 2019 Jan 11;20(2):. (PMID: 30642007)
Med Res Rev. 2022 Jan;42(1):259-305. (PMID: 33957000)
Acta Pharm Sin B. 2021 Jul;11(7):1708-1720. (PMID: 34386317)
Glia. 2001 Apr 1;34(1):18-26. (PMID: 11284016)
Acta Biomater. 2020 Aug;112:1-13. (PMID: 32470527)
Signal Transduct Target Ther. 2021 Jun 7;6(1):225. (PMID: 34099630)
J Clin Invest. 2022 Aug 1;132(15):. (PMID: 35912857)
Int J Stroke. 2016 Jun;11(4):399-411. (PMID: 27006423)
Science. 2022 Nov 4;378(6619):eadc9020. (PMID: 36378959)
Cells. 2023 Feb 24;12(5):. (PMID: 36899860)
Nat Rev Clin Oncol. 2023 Jan;20(1):33-48. (PMID: 36307534)
Ageing Res Rev. 2021 Sep;70:101376. (PMID: 34089901)
J Integr Plant Biol. 2022 Feb;64(2):342-370. (PMID: 34964268)
Front Neurol. 2022 Aug 30;13:951536. (PMID: 36110390)
Cell. 2015 Nov 19;163(5):1064-1078. (PMID: 26590417)
Eur J Pediatr. 2022 Mar;181(3):875-887. (PMID: 34820702)
Adv Mater. 2018 Jun;30(23):e1706759. (PMID: 29582476)
Biomater Adv. 2023 May;148:213379. (PMID: 36934713)
Front Pharmacol. 2021 Jan 27;11:586302. (PMID: 33584263)
Nanoscale Res Lett. 2022 Feb 16;17(1):27. (PMID: 35171358)
J Chem Neuroanat. 2021 Dec;118:102025. (PMID: 34520802)
J Neurovirol. 2005 Feb;11(1):82-7. (PMID: 15804965)
Curr Clin Pharmacol. 2016;11(3):191-210. (PMID: 27397091)
J Neurotrauma. 2018 Jul 1;35(13):1481-1494. (PMID: 29316834)
Prog Neurobiol. 2016 Sep;144:88-102. (PMID: 27132521)
Brain. 2022 Oct 21;145(10):3582-3593. (PMID: 34957486)
Nat Commun. 2022 Apr 4;13(1):1794. (PMID: 35379828)
Discov Nano. 2023 Mar 11;18(1):40. (PMID: 36969494)
Nature. 1988 Mar 31;332(6163):411-5. (PMID: 2451132)
ACS Biomater Sci Eng. 2024 May 13;10(5):3069-3085. (PMID: 38578110)
Int J Stroke. 2019 Feb;14(2):137-145. (PMID: 30489210)
Nature. 2021 Feb;590(7847):660-665. (PMID: 33597753)
Cytokine. 2024 May;177:156565. (PMID: 38442443)
J Am Chem Soc. 2023 Mar 15;145(10):5930-5940. (PMID: 36867864)
Int J Mol Sci. 2020 Nov 01;21(21):. (PMID: 33139635)
Drug Deliv. 2020 Dec;27(1):772-781. (PMID: 32400219)
Bioact Mater. 2022 Feb 11;14:430-442. (PMID: 35415281)
Neural Regen Res. 2024 Mar;19(3):650-656. (PMID: 37721297)
Front Pharmacol. 2024 Feb 26;15:1347529. (PMID: 38469401)
Prog Mol Biol Transl Sci. 2014;124:155-88. (PMID: 24751430)
Lancet Neurol. 2018 Sep;17(9):802-815. (PMID: 30129476)
Redox Biol. 2019 Jul;25:101109. (PMID: 30686776)
Biochem Pharmacol. 2023 Jan;207:115356. (PMID: 36455671)
Mol Ther. 2023 May 3;31(5):1207-1224. (PMID: 36245129)
Adv Biosyst. 2020 Nov;4(11):e2000174. (PMID: 33015972)
- Grant Information:
82372840 Natural Science Foundation of China; tstp20230659 Taishan Scholar Program of Shandong Province; 2022YFF0708704 National Key Research and Development Program of China Stem Cell and Translational Research
- Contributed Indexing:
Keywords: Astrocyte; Autophagy; Cell membrane-fused nanovesicle; Hypoxic ischemic encephalopathy; Neurovascular units
- Accession Number:
W36ZG6FT64 (Sirolimus)
0 (Endothelin-1)
- Publication Date:
Date Created: 20241219 Date Completed: 20241219 Latest Revision: 20250104
- Publication Date:
20250104
- Accession Number:
PMC11656965
- Accession Number:
10.1186/s12951-024-03053-8
- Accession Number:
39695691
No Comments.